MUMBAI: US health regulators have banned a drug production site in India belonging to Divi’s Laboratories Ltd due to manufacturing violations, sending the company’s shares down to a near three-year low on Wednesday.
This comes at a time when an increasingly protectionist stance by US President Donald Trump is threatening to make the operating environment tougher for India’s drugmakers that supply nearly a third of the medicines sold in the United States — the world’s largest healthcare market.
The US Food and Drug Administration’s ban on Divi’s Unit II factory in the eastern Indian state of Vizag — news of which was posted on the FDA website and seen by Reuters on Wednesday — is the second setback this month for India’s drugs industry.
The FDA found violations of manufacturing standards at Dr Reddy’s Laboratories Ltd’s drug plant, also in Vizag, during an inspection that ended on March 8, according to a copy of the inspection report seen by Reuters on Wednesday. Several analysts downgraded Divi’s stock to “sell” and others such as Jefferies maintained their “underperform” rating on Reddy’s stock, citing increasing regulatory challenges.
About 70 per cent of Divi’s total sales that depend on the plant are now under threat as other countries may go after the factory, prompted by the FDA action, said Edelweiss analysts.
Divi’s did not respond to an email requesting comment on Wednesday, but said in a statement to exchanges that it had started necessary measures to address the FDA’s concerns.
Shares in the company have plunged 18 per cent this week and were mired near a three-year low of Rs 611.45 ($9.34) on Wednesday. Dr Reddy’s stock hit Rs 2,555.20 earlier the day, also their lowest since 2014.
Dr Reddy’s said it plans to submit “a comprehensive response” to the FDA, which said it had found multiple repeat violations at the site — including problems that the agency had notified the company of as far back as in 2015. Issues listed in the report included data manipulation, as well as a Dr Reddy’s employee lying to FDA inspectors.
“We are confident in our ability to address these observations and will work with US FDA in resolving these issues,” Dr Reddy’s Chief Financial Officer Saumen Chakraborty said in an emailed statement.
Analysts, however, say the FDA report could be a risk for Dr Reddy’s all-important oncology pipeline, which has been a key area of focus for the company as it looks to improve its business in the United States, its largest market. — Reuters
Oman Observer is now on the WhatsApp channel. Click here
